Comparison · NCT03605862-ab0acf76
Nitazoxanide vs Placebo: Proportions Experiencing Complications of EV/RV Infection
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nitazoxanide vs Placebo: Proportions Experiencing Complications of EV/RV Infection. Trial comparisons, record NCT03605862-ab0acf76. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03605862-ab0acf76
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.042 | 0.0242 | 0.0719 | wilson | |
| Risk in group 2 | 0.0671 | 0.0439 | 0.101 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0252 | -0.0638 | 0.0128 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.625 | 0.311 | 1.26 | log | |
| Odds ratio, group 1 over group 2 | 0.609 | 0.292 | 1.27 | log | |
| Number needed to treat, for one fewer participant with the outcome on Nitazoxanide than on Placebo | 39.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nitazoxanide | Two Nitazoxanide 300 mg tablets orally twice daily for 5 days | 12 | 286 | OG000 |
| Group 2 | Placebo | Two placebo tablets orally twice daily for 5 days | 20 | 298 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportions Experiencing Complications of EV/RV Infection
- Description
Complications of colds due to EV/RV infection include pneumonia, otitis media, bronchitis, sinusitis, exacerbations of asthma or COPD, worsening of pre-existing health conditions, secondary infections requiring systemic antibiotic use, hospitalization due to cold or complications of the cold, and death due to cold or complications of the cold. Proportions experiencing complications of EV/RV infection were compared across treatment groups.
- Time frame
- 28 days
- Population
- The efficacy (intent-to-treat infected, ITTI) population consisted of 584 subjects (N=286 in NTZ group, N=298 in Placebo group) with laboratory-confirmed Enterovirus/Rhinovirus (EV/RV) infection.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
- NCT number
- NCT03605862
- Phases
- PHASE3
- Conditions
- Enterovirus, Rhinovirus
- Interventions
- Nitazoxanide, Placebo
- Lead sponsor
- Romark Laboratories L.C.
- Results first posted
- 2022-04-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03605862?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03605862-ab0acf76